GRI Bio, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
GRI Bio amended and restated its 2018 Equity Incentive Plan, effective September 21, 2026 (subject to stockholder approval). The Plan authorizes 581,480 shares initially, plus annual increases of up to 4% of outstanding shares through January 1, 2036. No material changes to plan mechanics are disclosed; this is a routine restating of existing plan terms.
Why this rating
Routine plan amendment/restatement. No new grants, no share cancellations, no material financial impact disclosed. At $1.5M market cap, equity plan administration is standard practice, not a business driver.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.